Friday, April 11, 2025, Denver, Colorado, 6:00 AM – 7:30 AM Mountain Time (8:00 AM – 9:30 AM Eastern Time)

Understanding the Current Paradigm and New Approaches: The Role of DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer

A Complimentary NCPD Symposium Held During the 50th Annual ONS Congress

 

 

 

Register for in-person Register for webcast

Location
Hyatt Regency Denver
at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234

Program Schedule — Mountain Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Meeting Room
Capitol Ballroom (Fourth Floor)
 
 
Faculty
Anne Chiang, MD, PhD
Associate Professor
Yale University School of Medicine
Associate Yale Cancer Center Director
Smilow Cancer Hospital
New Haven, Connecticut

Elizabeth Krueger, NP
Nurse Practitioner
Massachusetts General Hospital Center
for Thoracic Cancers
Boston, Massachusetts


Beth Sandy, MSN, CRNP, FAPO
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Erin Schenk, MD, PhD
Assistant Professor
Thoracic Oncology
Division of Medical Oncology
Department of Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado



Meeting space has been assigned to provide a satellite symposium supported by Amgen Inc during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Biology of Small Cell Lung Cancer (SCLC) and Historical Disease Management

  • Pathophysiology of SCLC; similarities and differences between SCLC and non-small cell lung cancer
  • Long-term prognosis and typical clinical course of SCLC
  • Role of and outcomes achieved with chemotherapy in combination with anti-PD-1/PD-L1 antibodies as first-line treatment for patients with extensive-stage (ES) SCLC
  • Therapeutic options available for patients with relapsed/refractory (R/R) ES-SCLC

Biological Rationale for the Evaluation of DLL3-Targeting Bispecific T-Cell Engagers (BiTES) in SCLC

  • Incidence of DLL3 overexpression in patients with SCLC
  • Scientific rationale for the selection of DLL3 and CD3 as targets for BiTEs in SCLC
  • Mechanism of action and structural components of DLL3-targeting BiTEs
  • Similarities and differences among BiTEs, bispecific antibodies and chimeric antigen receptor T-cell therapy

Current Role of Tarlatamab in the Management of SCLC

  • Pivotal clinical trial results with tarlatamab for patients with R/R SCLC
  • FDA accelerated approval for tarlatamab and optimal integration into current clinical algorithms
  • Design, eligibility criteria and key efficacy and safety endpoints for the confirmatory Phase III DeLLphi-304 trial evaluating tarlatamab versus standard therapy for R/R SCLC

Identification of Appropriate Candidates for Treatment with Tarlatamab

  • Patient- and disease-related factors, including comorbidities, to be considered before administering tarlatamab
  • Feasibility of administering tarlatamab to older patients or those with a poor performance status
  • Relative and absolute contraindications to the use of tarlatamab

Cytokine Release Syndrome (CRS) Related to the Use of Tarlatamab

  • Pathophysiology of the CRS observed with tarlatamab
  • Frequency, severity, typical time course and common signs and symptoms of CRS
  • Optimal patient monitoring for early detection of CRS
  • Guideline-endorsed approaches for mitigation and management of CRS; role of corticosteroids, tocilizumab and other supportive care interventions

Neurotoxicity Related to the Use of Tarlatamab

  • Pathophysiology of immune effector cell-associated neurotoxicity syndrome (ICANS)
  • Clinical presentation of ICANS or neurotoxicity and common symptoms, including delirium, dysphasia, lethargy, difficulty concentrating and confusion
  • Strategies to diagnose and grade ICANS/neurotoxicity
  • Optimal approaches to the management of ICANS/neurotoxicity

Module 7: Other Tolerability and Toxicity Concerns with Tarlatamab

  • Spectrum, frequency and severity of other common tolerability concerns with tarlatamab, such as cyto-penias, infections, hypersensitivity, hepatotoxicity and fatigue
  • Counseling patients about the importance of promptly reporting symptoms of common and less common adverse events
  • Recommended monitoring of complete blood counts and other laboratory values for patients receiving tarlatamab
  • Strategies to manage side effects of tarlatamab in routine practice; appropriate thresholds for dose modification and treatment discontinuation

Other Practical Considerations with the Use of Tarlatamab

  • Route of administration, recommended step-up dosing and optimal duration of treatment
  • Appropriate premedication and prophylaxis for patients with SCLC about to initiate treatment with tarlatamab
  • Rationale for patient monitoring in a healthcare environment after cycle 1 day 1 and day 8 dosing

Future Directions in the Use of Tarlatamab

  • Educating patients about the potential advantages of taking part in a clinical research study
  • Early results with and ongoing evaluation of tarlatamab with a PD-L1 inhibitor as maintenance therapy after first-line chemoimmunotherapy for ES-SCLC
  • Other novel investigational strategies with tarlatamab

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise the scientific rationale for and mechanism of action of the DLL3-targeting bispecific T-cell engagers (BiTEs) used as therapy for patients with small cell lung cancer (SCLC).
  • Evaluate available research findings with DLL3-targeting BiTEs for relapsed/refractory SCLC, and counsel patients with this disease regarding the risks and benefits of this novel approach.
  • Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with DLL3-targeting BiTEs employed in the care of patients with SCLC, and develop strategies to optimally identify and manage the symptoms of these side effects.
  • Recognize the spectrum, frequency and severity of other adverse events associated with DLL3-targeting BiTEs, such as infections, cytopenias and hepatoxicity, and consider recommended approaches to prevent, ameliorate and manage these side effects.
  • Appreciate the practical administration requirements associated with DLL3-targeting BiTEs in order to appropriately educate eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/BiTEsSCLC/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Krueger has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Chiang — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Fosun Pharma, Genentech, a member of the Roche Group, Janssen Biotech Inc, Zai Lab; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Zai Lab; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Internal Education Lecture on SCLC: Jazz Pharmaceuticals Inc. Ms Sandy — Advisory Committees: Pfizer Inc; Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc. Dr Schenk — Advisory Committees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, CDR-Life, Harpoon Therapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Takeda Pharmaceuticals USA Inc, Thetis Pharmaceuticals LLC; Consulting Agreements: Aadi Bioscience, ALIGN2ACTION Inc, Axon Advisors, BeiGeneius, Expert Connect, GlobalData, Guidepoint Global LLC, HCG, Slingshot Insights, The Scieomics Group, Third Bridge, WC Communications; Data and Safety Monitoring Boards/Committees: Amgen Inc; Speakers Bureaus: Curio Science, Harpoon Therapeutics, Janssen Biotech Inc, Nuvation Bio; Stock Options — Private Companies: Thetis Pharmaceuticals LLC; Nonrelevant Financial Relationships: ASCO Direct, Cancer Therapy Advisor, Horizon CME, IDEOlogy Health, Medscape, OncLive, ROS1ders.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from Amgen Inc.

Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234

Meeting Room
Capitol Ballroom (Fourth Floor)

The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 ONS Congress.

IN-PERSON Registration
Thank you for your interest in our NCPD program taking place in Denver, Colorado. At this time online registration for in-person attendance is closed for this event. LIMITED SEATING IS STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 5:30 AM Mountain Time on Friday, April 11th. If you are interested in attending, please visit our registration desk located outside the Capital Ballroom (Meeting Level 4) at the Hyatt Regency Denver at Colorado Convention Center (650 15th Street), which is a 5-minute walk to the Colorado Convention Center.

Please note, onsite registration does not guarantee seating or participation in the meal service, which will be based on availability. 

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com.
WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.